Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Quality of Life | 43 | 2025 | 1225 | 5.920 |
Why?
|
| Sickness Impact Profile | 16 | 2013 | 46 | 2.550 |
Why?
|
| Surveys and Questionnaires | 28 | 2025 | 2674 | 2.450 |
Why?
|
| Psychometrics | 22 | 2025 | 376 | 2.130 |
Why?
|
| Health Surveys | 11 | 2023 | 313 | 2.070 |
Why?
|
| Self Report | 10 | 2020 | 375 | 1.820 |
Why?
|
| Disability Evaluation | 6 | 2017 | 217 | 1.260 |
Why?
|
| Factor Analysis, Statistical | 8 | 2020 | 97 | 1.190 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2023 | 131 | 1.160 |
Why?
|
| Health Status | 10 | 2025 | 435 | 1.100 |
Why?
|
| Reproducibility of Results | 16 | 2025 | 1650 | 1.070 |
Why?
|
| Health Status Indicators | 3 | 2015 | 93 | 1.070 |
Why?
|
| Models, Statistical | 4 | 2020 | 308 | 1.010 |
Why?
|
| Data Collection | 4 | 2014 | 383 | 0.990 |
Why?
|
| Adult | 36 | 2025 | 16788 | 0.890 |
Why?
|
| Middle Aged | 38 | 2025 | 17553 | 0.880 |
Why?
|
| Aged | 35 | 2025 | 14393 | 0.860 |
Why?
|
| Headache | 4 | 2025 | 58 | 0.850 |
Why?
|
| Cost of Illness | 5 | 2016 | 162 | 0.830 |
Why?
|
| Pharyngitis | 1 | 2023 | 13 | 0.810 |
Why?
|
| Chronic Disease | 7 | 2023 | 753 | 0.780 |
Why?
|
| Smoking | 3 | 2020 | 865 | 0.780 |
Why?
|
| Severity of Illness Index | 5 | 2024 | 1542 | 0.770 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 89 | 0.760 |
Why?
|
| Male | 43 | 2025 | 29823 | 0.750 |
Why?
|
| Multiple Chronic Conditions | 1 | 2022 | 39 | 0.730 |
Why?
|
| Activities of Daily Living | 9 | 2012 | 291 | 0.720 |
Why?
|
| Mindfulness | 1 | 2021 | 70 | 0.680 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2019 | 153 | 0.670 |
Why?
|
| Humans | 58 | 2025 | 63299 | 0.670 |
Why?
|
| Female | 38 | 2025 | 32793 | 0.650 |
Why?
|
| Prostatic Neoplasms | 3 | 2020 | 416 | 0.650 |
Why?
|
| Cause of Death | 1 | 2020 | 221 | 0.640 |
Why?
|
| Software | 3 | 2012 | 389 | 0.640 |
Why?
|
| Aged, 80 and over | 15 | 2025 | 5449 | 0.610 |
Why?
|
| Autism Spectrum Disorder | 1 | 2021 | 180 | 0.580 |
Why?
|
| Young Adult | 11 | 2025 | 4686 | 0.530 |
Why?
|
| Knee Injuries | 1 | 2017 | 47 | 0.520 |
Why?
|
| Fatigue | 2 | 2014 | 111 | 0.520 |
Why?
|
| Adolescent | 17 | 2024 | 6241 | 0.520 |
Why?
|
| Heart Failure | 3 | 2023 | 915 | 0.490 |
Why?
|
| Osteoarthritis | 3 | 2020 | 142 | 0.480 |
Why?
|
| Translating | 1 | 2015 | 18 | 0.470 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2017 | 126 | 0.460 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2013 | 335 | 0.460 |
Why?
|
| Comorbidity | 7 | 2020 | 1122 | 0.440 |
Why?
|
| Drug Therapy | 1 | 2014 | 56 | 0.430 |
Why?
|
| Cross-Sectional Studies | 9 | 2024 | 2569 | 0.410 |
Why?
|
| Information Systems | 1 | 2013 | 29 | 0.410 |
Why?
|
| United States | 15 | 2025 | 7829 | 0.400 |
Why?
|
| Musculoskeletal Diseases | 2 | 2020 | 103 | 0.400 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2014 | 769 | 0.380 |
Why?
|
| User-Computer Interface | 2 | 2012 | 125 | 0.380 |
Why?
|
| Monitoring, Ambulatory | 1 | 2012 | 57 | 0.370 |
Why?
|
| Osteoarthritis, Knee | 1 | 2017 | 385 | 0.370 |
Why?
|
| Research Design | 2 | 2014 | 573 | 0.370 |
Why?
|
| Acute Coronary Syndrome | 1 | 2015 | 253 | 0.360 |
Why?
|
| Models, Theoretical | 4 | 2015 | 268 | 0.360 |
Why?
|
| Outpatients | 1 | 2012 | 142 | 0.350 |
Why?
|
| Treatment Outcome | 8 | 2017 | 5655 | 0.340 |
Why?
|
| Calibration | 4 | 2015 | 66 | 0.330 |
Why?
|
| Mental Health | 5 | 2020 | 371 | 0.320 |
Why?
|
| Anemia | 1 | 2010 | 127 | 0.310 |
Why?
|
| Stress, Psychological | 2 | 2021 | 469 | 0.280 |
Why?
|
| Restless Legs Syndrome | 1 | 2007 | 8 | 0.270 |
Why?
|
| Subacute Care | 1 | 2007 | 9 | 0.260 |
Why?
|
| Migraine Disorders | 2 | 2003 | 41 | 0.260 |
Why?
|
| Managed Care Programs | 2 | 2004 | 89 | 0.250 |
Why?
|
| Longitudinal Studies | 5 | 2017 | 1255 | 0.240 |
Why?
|
| Disease Management | 1 | 2007 | 232 | 0.240 |
Why?
|
| Nervous System Diseases | 1 | 2007 | 107 | 0.230 |
Why?
|
| Program Evaluation | 1 | 2007 | 487 | 0.230 |
Why?
|
| Cough | 2 | 2024 | 183 | 0.220 |
Why?
|
| Affective Symptoms | 1 | 2004 | 15 | 0.220 |
Why?
|
| Low Back Pain | 1 | 2025 | 114 | 0.220 |
Why?
|
| Computer Systems | 1 | 2003 | 14 | 0.210 |
Why?
|
| Hyperkalemia | 1 | 2023 | 20 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2010 | 695 | 0.210 |
Why?
|
| Immunocompromised Host | 1 | 2024 | 107 | 0.210 |
Why?
|
| Analysis of Variance | 2 | 2016 | 608 | 0.210 |
Why?
|
| Double-Blind Method | 6 | 2014 | 738 | 0.210 |
Why?
|
| Physical and Rehabilitation Medicine | 1 | 2003 | 2 | 0.210 |
Why?
|
| Psoriasis | 1 | 2004 | 55 | 0.210 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 310 | 0.210 |
Why?
|
| Rehabilitation | 1 | 2003 | 7 | 0.200 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 161 | 0.200 |
Why?
|
| Interpersonal Relations | 2 | 2019 | 151 | 0.200 |
Why?
|
| Multimorbidity | 1 | 2022 | 48 | 0.190 |
Why?
|
| Life Tables | 1 | 2020 | 23 | 0.170 |
Why?
|
| Marital Status | 1 | 2020 | 45 | 0.170 |
Why?
|
| Confidence Intervals | 3 | 2013 | 240 | 0.170 |
Why?
|
| Asthma | 1 | 2025 | 440 | 0.170 |
Why?
|
| SEER Program | 1 | 2020 | 74 | 0.170 |
Why?
|
| Finasteride | 2 | 2012 | 5 | 0.170 |
Why?
|
| Diabetes Mellitus | 1 | 2025 | 538 | 0.160 |
Why?
|
| Depression | 1 | 2007 | 892 | 0.160 |
Why?
|
| Medicare | 1 | 2004 | 612 | 0.160 |
Why?
|
| Japan | 3 | 2023 | 59 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 863 | 0.160 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 501 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 311 | 0.150 |
Why?
|
| Social Support | 1 | 2021 | 371 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2021 | 1007 | 0.140 |
Why?
|
| Renal Dialysis | 1 | 2019 | 198 | 0.140 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 40 | 0.130 |
Why?
|
| Age Factors | 1 | 2020 | 1558 | 0.130 |
Why?
|
| Personal Satisfaction | 2 | 2014 | 82 | 0.130 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 319 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2012 | 568 | 0.130 |
Why?
|
| Germany | 1 | 2015 | 54 | 0.120 |
Why?
|
| Thyroid Diseases | 1 | 2015 | 26 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 2457 | 0.120 |
Why?
|
| Self-Assessment | 2 | 2007 | 60 | 0.120 |
Why?
|
| Single-Blind Method | 1 | 2015 | 143 | 0.110 |
Why?
|
| Concept Formation | 1 | 2014 | 18 | 0.110 |
Why?
|
| Adaptation, Psychological | 2 | 2007 | 265 | 0.110 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2014 | 1 | 0.110 |
Why?
|
| Tobacco Products | 1 | 2015 | 80 | 0.110 |
Why?
|
| Somatostatin | 1 | 2014 | 21 | 0.110 |
Why?
|
| Anticarcinogenic Agents | 2 | 2012 | 78 | 0.110 |
Why?
|
| Goiter | 1 | 2014 | 9 | 0.110 |
Why?
|
| Smoking Prevention | 1 | 2015 | 162 | 0.110 |
Why?
|
| Methotrexate | 2 | 2006 | 80 | 0.100 |
Why?
|
| Antirheumatic Agents | 3 | 2007 | 220 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2020 | 2076 | 0.100 |
Why?
|
| Patient Preference | 1 | 2014 | 84 | 0.100 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2012 | 6 | 0.100 |
Why?
|
| Emotions | 1 | 2014 | 223 | 0.090 |
Why?
|
| Computers, Handheld | 1 | 2012 | 38 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 834 | 0.090 |
Why?
|
| Dyspnea | 1 | 2012 | 124 | 0.090 |
Why?
|
| Role Playing | 1 | 2010 | 8 | 0.090 |
Why?
|
| Stroke | 1 | 2020 | 1192 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2017 | 2569 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2023 | 3283 | 0.090 |
Why?
|
| Depressive Disorder | 1 | 2013 | 284 | 0.090 |
Why?
|
| Risk Factors | 1 | 2020 | 5343 | 0.080 |
Why?
|
| Prevalence | 2 | 2012 | 1377 | 0.080 |
Why?
|
| Qualitative Research | 1 | 2014 | 684 | 0.080 |
Why?
|
| Immunoconjugates | 2 | 2007 | 90 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 433 | 0.070 |
Why?
|
| Models, Psychological | 2 | 2010 | 97 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 455 | 0.070 |
Why?
|
| Erectile Dysfunction | 1 | 2007 | 24 | 0.070 |
Why?
|
| International Cooperation | 2 | 2006 | 90 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 694 | 0.060 |
Why?
|
| Program Development | 1 | 2007 | 207 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2007 | 510 | 0.060 |
Why?
|
| United Kingdom | 1 | 2024 | 80 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2004 | 44 | 0.050 |
Why?
|
| Potassium | 1 | 2023 | 101 | 0.050 |
Why?
|
| Intellectual Property | 1 | 2003 | 6 | 0.050 |
Why?
|
| Telephone | 1 | 2003 | 119 | 0.050 |
Why?
|
| Polyhydroxyethyl Methacrylate | 1 | 2002 | 6 | 0.050 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2002 | 27 | 0.050 |
Why?
|
| Tetrazoles | 1 | 2002 | 22 | 0.050 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2003 | 45 | 0.050 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2002 | 49 | 0.050 |
Why?
|
| Acute Disease | 1 | 2024 | 672 | 0.050 |
Why?
|
| Time Factors | 2 | 2007 | 3762 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2003 | 158 | 0.050 |
Why?
|
| Risk Adjustment | 1 | 2002 | 94 | 0.050 |
Why?
|
| Intermittent Claudication | 1 | 2002 | 56 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 63 | 0.050 |
Why?
|
| Communication | 1 | 2007 | 571 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2004 | 233 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2002 | 198 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2003 | 289 | 0.040 |
Why?
|
| Walking | 1 | 2002 | 238 | 0.040 |
Why?
|
| Social Participation | 1 | 2020 | 15 | 0.040 |
Why?
|
| Cultural Competency | 1 | 2020 | 52 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 63 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 1146 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 459 | 0.040 |
Why?
|
| Cognition | 1 | 2003 | 483 | 0.040 |
Why?
|
| Hypertension | 1 | 2004 | 585 | 0.040 |
Why?
|
| Algorithms | 1 | 2003 | 1000 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 777 | 0.030 |
Why?
|
| Child | 2 | 2024 | 4525 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 254 | 0.030 |
Why?
|
| Pain | 1 | 2020 | 406 | 0.030 |
Why?
|
| Abatacept | 2 | 2007 | 65 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 53 | 0.030 |
Why?
|
| Psychological Theory | 1 | 2011 | 26 | 0.020 |
Why?
|
| Educational Status | 1 | 2011 | 275 | 0.020 |
Why?
|
| Self Concept | 1 | 2010 | 111 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2010 | 147 | 0.020 |
Why?
|
| Computer-Assisted Instruction | 1 | 2010 | 80 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2011 | 217 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 417 | 0.020 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2007 | 1 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 72 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 373 | 0.010 |
Why?
|
| Los Angeles | 1 | 2004 | 12 | 0.010 |
Why?
|
| Chicago | 1 | 2004 | 27 | 0.010 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 60 | 0.010 |
Why?
|
| Fee-for-Service Plans | 1 | 2004 | 69 | 0.010 |
Why?
|
| Specialization | 1 | 2004 | 81 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2004 | 47 | 0.010 |
Why?
|
| Medicine | 1 | 2004 | 57 | 0.010 |
Why?
|
| Boston | 1 | 2004 | 252 | 0.010 |
Why?
|
| Europe | 1 | 2004 | 194 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 498 | 0.010 |
Why?
|
| Intracranial Arterial Diseases | 1 | 2002 | 7 | 0.010 |
Why?
|
| Linear Models | 1 | 2004 | 409 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 149 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 194 | 0.010 |
Why?
|
| Etanercept | 1 | 2002 | 32 | 0.010 |
Why?
|
| Exercise Test | 1 | 2002 | 252 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2002 | 345 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2004 | 690 | 0.010 |
Why?
|